|
1
|
Paes MF, Daltoé RD, Madeira KP, et al: A
retrospective analysis of clinicopathological and prognostic
characteristics of ovarian tumors in the state of Espírito Santo,
Brazil. J Ovarian Res. 4:142011. View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hudson LG, Zeineldin R and Stack MS:
Phenotypic plasticity of neoplastic ovarian epithelium: unique
cadherin profiles in tumor progression. Clin Exp Metastasis.
25:643–655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Domenighetti G, Moccia A and Gayer R:
Observational case-control study of non-invasive ventilation in
patients with ARDS. Monaldi Arch Chest Dis. 69:5–10.
2008.PubMed/NCBI
|
|
5
|
Teoh D and Secord AA: Antiangiogenic
agents in combination with chemotherapy for the treatment of
epithelial ovarian cancer. Int J Gynecol Cancer. 22:348–359. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Usha L, Sill MW, Darcy KM, et al: A
Gynecologic Oncology Group phase II trial of the protein kinase
C-beta inhibitor, enzastaurin and evaluation of markers with
potential predictive and prognostic value in persistent or
recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol. 121:455–461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu H, Yao L, Mei J and Li F: Development
of synthetic of peptide-functionalized liposome for enhanced
targeted ovarian carcinoma therapy. Int J Clin Exp Pathol.
8:207–216. 2015.PubMed/NCBI
|
|
8
|
Kannan K, Coarfa C, Chao PW, et al:
Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated
AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc
Natl Acad Sci USA. 112:E1272–E1277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gurler H, Yu Y, Choi J, Kajdacsy-Balla AA
and Barbolina MV: Three-dimensional collagen type I matrix
up-regulates nuclear isoforms of the microtubule associated protein
tau implicated in resistance to paclitaxel therapy in ovarian
carcinoma. Int J Mol Sci. 16:3419–3433. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morris LG, Veeriah S and Chan TA: Genetic
determinants at the interface of cancer and neurodegenerative
disease. Oncogene. 29:3453–3464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gan GN, Weickhardt AJ, Scheier B, et al:
Stereotactic radiation therapy can safely and durably control sites
of extra-central nervous system oligoprogressive disease in
anaplastic lymphoma kinase-positive lung cancer patients receiving
crizotinib. Int J Radiat Oncol Biol Phys. 88:892–898. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Catalano A, Caprari P, Rodilossi S, et al:
Cross-talk between vascular endothelial growth factor and
semaphorin-3A pathway in the regulation of normal and malignant
mesothelial cell proliferation. FASEB J. 18:358–360. 2004.
|
|
13
|
Cao L, Liu X, Lin EJ, et al: Environmental
and genetic activation of a brain-adipocyte BDNF/leptin axis causes
cancer remission and inhibition. Cell. 142:52–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Casazza A, Fu X, Johansson I, et al:
Systemic and targeted delivery of semaphorin 3A inhibits tumor
angiogenesis and progression in mouse tumor models. Arterioscler
Thromb Vasc Biol. 31:741–749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maione F, Molla F, Meda C, et al:
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks
tumor growth and normalizes tumor vasculature in transgenic mouse
models. J Clin Invest. 119:3356–3372. 2009.PubMed/NCBI
|
|
16
|
Sakurai A, Gavard J, Annas-Linhares Y, et
al: Semaphorin 3E initiates antiangiogenic signaling through plexin
D1 by regulating Arf6 and R-Ras. Mol Cell Biol. 30:3086–3098. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Varshavsky A, Kessler O, Abramovitch S, et
al: Semaphorin-3B is an angiogenesis inhibitor that is inactivated
by furin-like pro-protein convertases. Cancer Res. 68:6922–6931.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng C, Zhou Q, Wu F, et al: Semaphorin3F
down-regulates the expression of integrin alpha(v)beta3 and
sensitizes multicellular tumor spheroids to chemotherapy via the
neuropilin-2 receptor in vitro. Chemotherapy. 55:344–352. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Staton CA, Koay I, Wu JM, Hoh L, Reed MW
and Brown NJ: Neuropilin-1 and neuropilin-2 expression in the
adenoma-carcinoma sequence of colorectal cancer. Histopathology.
62:908–915. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jia H, Cheng L, Tickner M, Bagherzadeh A,
Selwood D and Zachary I: Neuropilin-1 antagonism in human carcinoma
cells inhibits migration and enhances chemosensitivity. Br J
Cancer. 102:541–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chaudhary B, Khaled YS, Ammori BJ and
Elkord E: Neuropilin 1: function and therapeutic potential in
cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
|
|
22
|
Bruder D, Probst-Kepper M, Westendorf AM,
et al: Neuropilin-1: A surface marker of regulatory T cells. Eur J
Immunol. 34:623–630. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Renand A, Milpied P, Rossignol J, et al:
Neuropilin-1 expression characterizes T follicular helper (Tfh)
cells activated during B cell differentiation in human secondary
lymphoid organs. PLoS One. 8:e855892013. View Article : Google Scholar
|
|
24
|
Chaudhary B, Khaled YS, Ammori BJ and
Elkord E: Neuropilin 1: function and therapeutic potential in
cancer. Cancer Immunol Immunother. 63:81–99. 2014. View Article : Google Scholar
|
|
25
|
Kamiya T, Kawakami T, Abe Y, et al: The
preserved expression of neuropilin (NRP) 1 contributes to a better
prognosis in colon cancer. Oncol Rep. 15:369–373. 2006.PubMed/NCBI
|
|
26
|
Wu YY, Chen YL, Jao YC, et al: miR-320
regulates tumor angiogenesis driven by vascular endothelial cells
in oral cancer by silencing neuropilin 1. Angiogenesis. 17:247–260.
2014. View Article : Google Scholar
|
|
27
|
Wan LY, Deng J, Xiang XJ, Zhang L, et al:
miR-320 enhances the sensitivity of human colon cancer cells to
chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res
Commun. 457:125–32. 2015. View Article : Google Scholar
|
|
28
|
Wu YY, Chen YL, Jao YC, Hsieh IS, Chang KC
and Hong TM: miR-320 regulates tumor angiogenesis driven by
vascular endothelial cells in oral cancer by silencing neuropilin
1. Angiogenesis. 17:247–260. 2014. View Article : Google Scholar
|
